ILYM15080 / ZUMA-2 / Patrick Reagan
Research Question:
Is KTE-C19 safe and effective in treating your lymphoma when administered after a
3 day course of chemotherapy?
Basic Study Information
Purpose:
The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel
(KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)
Location: Cancer Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02601313?term=Kite+102&rank=1
Study Reference #: ILYM-15080
Lead Researcher (Principal Investigator)
Lead Researcher:
Patrick Reagan
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Learn More About These Conditions
More information about Lymphoma, Mantle-Cell
More information about Mantle cell lymphoma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search